News & Reports

News and Reports

Select year

2022 2021 2020 2019 2018 Earlier
shown/page
10
5 10 15 20

2021.12.01

Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Peripheral T-Cell Lymphoma(PTCL) in Japan
Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Peripheral T-Cell Lymphoma(PTCL) in Japan

Full text

2020.06.24

Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Adult T-cell Leukemia/lymphoma in Japan
Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Adult T-cell Leukemia/lymphoma in Japan

Full text

2021.04.16

Chipscreen received a Phase 1b/2 clinical trial of Chiauranib/CS2164 IND clearance from the US Food and Drug Administration (FDA)
Chipscreen received a Phase 1b/2 clinical trial of Chiauranib/CS2164 IND clearance from the US Food and Drug Administration (FDA)

Full text

2021.01.11

Pivotal phase III clinical trial IND submission of the original innovative anticancer drug Chiauranib for the treatment of small cell lung cancer was accepted by the Center of Drug Evaluation of the N
Pivotal phase III clinical trial IND submission of the original innovative anticancer drug Chiauranib for the treatment of small cell lung cancer was accepted by the Center of Drug Evaluation of the N

Full text

2020.12.16

Chipscreen and HISUN reach a strategic cooperation
Chipscreen and HISUN reach a strategic cooperation

Full text

2020.03.24

Chipscreen Biosciences's Original New Drug CS12192: Investigational New Drug (IND) Application Accepted
Chipscreen Biosciences's Original New Drug CS12192: Investigational New Drug (IND) Application Accepted

Full text

2019.12.03

National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) for Breast Cancer Indication
National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) for Breast Cancer Indication

Full text

2019.10.09

Chipscreen and Novogene enter a strategic partnership for companion diagnostics development
Chipscreen and Novogene enter a strategic partnership for companion diagnostics development

Full text

2019.09.20

Chipscreeen Biosciences’s Original New Drug Bilessglu® (for Type 2 Diabetes): Commercialization Application Accepted
Chipscreeen Biosciences’s Original New Drug Bilessglu® (for Type 2 Diabetes): Commercialization Application Accepted

Full text

2018.05.30

Good News! CHIPSCREEN BIOSCIENCES Is Approved to Be Provincial Engineering Research Center
Good News! CHIPSCREEN BIOSCIENCES Is Approved to Be Provincial Engineering Research Center

Full text
Media contact

Media contact

  • Media contact

    (+86)0755-36993500

  • Media contact

    pr@chipscreen.com